| John A Petrie, MD | |
|
5645 Main St, Flushing, NY 11355-5045 | |
| (718) 670-2493 | |
| (516) 437-4167 |
| Full Name | John A Petrie |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 36 Years |
| Location | 5645 Main St, Flushing, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275565822 | NPI | - | NPPES |
| 01654728 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 183590 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian/queens | Flushing, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Valley Anesthesiology Pa | 0749194868 | 163 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
It would surprise no one that pursuing a graduate degree can be a stressful endeavor, and for students who are transgender and nonbinary (TNB), the atmosphere can become toxic, according to University of Houston researcher Nathan Grant Smith.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
› Verified 5 days ago
| Entity Name | Northern Valley Anesthesiology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245289487 PECOS PAC ID: 0749194868 Enrollment ID: O20151023001503 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
It would surprise no one that pursuing a graduate degree can be a stressful endeavor, and for students who are transgender and nonbinary (TNB), the atmosphere can become toxic, according to University of Houston researcher Nathan Grant Smith.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John A Petrie, MD Po Box 27842, New York, NY 10087-7842 Ph: (718) 670-1651 | John A Petrie, MD 5645 Main St, Flushing, NY 11355-5045 Ph: (718) 670-2493 |
News Archive
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
It would surprise no one that pursuing a graduate degree can be a stressful endeavor, and for students who are transgender and nonbinary (TNB), the atmosphere can become toxic, according to University of Houston researcher Nathan Grant Smith.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
› Verified 5 days ago
Dr. Oscar Roldan, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 14030 Beech Ave Apt 4t, Flushing, NY 11355 Phone: 407-506-6751 | |
Deemah Stalhamer, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4500 Parsons Blvd, Flushing, NY 11355 Phone: 718-670-5631 Fax: 718-670-4446 | |
Adam Hom, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 10201 66th Rd, Flushing, NY 11375 Phone: 917-837-2030 | |
William E Perez, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4500 Parsons Blvd, Flushing, NY 11355 Phone: 718-670-5631 Fax: 718-670-4446 | |
Michelle Evans, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4500 Parsons Blvd, Flushing, NY 11355 Phone: 718-670-5631 Fax: 718-670-4446 | |
Dr. Usha Krishnamurthy, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5516 Main St, Suite 1b, Flushing, NY 11355 Phone: 718-461-0017 Fax: 718-461-0018 | |
Rafaelita B Samala, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3609 Main St, Suite 201, Flushing, NY 11354 Phone: 718-321-7558 |